Can I create a form in Decile Hub that I can use to gather name, address, email, and phone number information from prospects and have this data create a person directly? The use case is that I want to send out an invitation to people to attend an event, familiarising them with the New Zealand Golden Visa. My fund is an eligible investment under this program, and I want the invite to include a link that allows them to enter the event information and add it to the Decile Person DB.
Does anyone have "fund advisors" helping them? Meaning they will help open their network for a percentage. Do we need to talk to legal about this? Do we have a legal team?
As part of Sprint 0 Set 3 we are asked to "Next, test your VC 101 knowledge with the quizzes and additional research available here (https://decilegroup.com/ai)" There are is no quiz at this link nor anywhere on the decile hub or decile group website. Has this been moved or removed?
I am getting this message, but clicking on it doesn't take me to the checklist (just to the main dashboard). I'm trying to figure out what the missing step is to complete the task.
I don't know if anyone else is getting this, but the default time zone when creating a new event is coming up as Mountain Time for me, and I'm in Central Time.
A task for Calvin Yoon has been updated from "Automated" to "Manual" in the Investors pipeline. Hub attempted to run an automatic task for Calvin Yoon but it was unsuccessful and the automation has been paused. See details below | Firm name: | Reflect Ventures | Pipeline: | Investors | Stage: | S.010 Cold Add | Prospect: | Calvin Yoon <No email> | Email action: | https://reflectventures.decilehub.com/email_templates/3830716?pipeline_id=Lnp4lMvn | Error(s): | This prospect does not have an email address | Developer notes: [{"variable_name":"","error_type":"This prospect does not have an email address","variable_type":null,"variable_id":null}] |
There should be a link directly to Calvin Yoon
Clicking on Investors link takes me to a different pipeline
@Woody Butler
Why does my decilepro.com page show this spew on the right side of my page in preview mode? "The Pharmacy Innovator Fund is a $5M seed-stage fund investing in technology companies modernizing U.S. pharmacy infrastructure. Our focus spans both B2B and B2C solutions that improve pharmacy economics and enable pharmacists to expand their clinical service offerings at scale. FUND SHEET - PHARMACY INNOVATOR FUND FUND OVERVIEW Fund Name: Pharmacy Innovator Fund Fund Structure: Start Fund (Series of Decile Start Fund, LP) Fund Size: $5,000,000 Investment Stage: Seed (Pre-seed to Seed) Target Sectors: Pharmacy technology, healthcare infrastructure, B2B/B2C software Geography: United States Fund Life: 10 years (+ 2 one-year extensions) Vintage Year: 2025 Close Minimum: $100,000 ECONOMICS Management Fee Structure: 1% annually (Start Fund model) - Year 1: 5% of fund size ($250,000) - Year 2: 5% of fund size ($250,000) - Years 3-10: 0% - Total Management Fees: $500,000 (10% of fund) Carried Interest: 18% (to Decile Group as fund sponsor) Preferred Return (Hurdle): 8% annually to LPs Fund Expenses: $0 (all operational costs covered by Decile Group) Investible Capital: $4,500,000 (90% of fund size) INVESTMENT STRATEGY Target Number of Investments: 20 companies Average Investment Size: $225,000 Target Ownership Range: 3-5% per company Reserve Ratio: 30% for follow-on investments Initial Investment Capital: $3,150,000 (70% of investible capital) Follow-on Reserve Capital: $1,350,000 (30% of investible capital) PORTFOLIO CONSTRUCTION Stage Focus: Pre-seed to Seed Target Entry Valuation Range: $3M - $8M post-money Check Size Range: $150K - $350K initial investment Expected Dilution at Exit: 50-70% from initial ownership Target Hold Period: 5-8 years Investment Pace: 8-10 companies Year 1, 6-8 companies Year 2, 4-6 companies Year 3 ALLOCATION TABLE | Metric | Value | | Number of Portfolio Companies | 20 | | Average Investment Amount | $225,000 | | Target Entry Valuation | $5,500,000 | | Target Ownership at Investment | 4.1% | RETURN PROJECTIONS - CONSERVATIVE CASE Failure Rate: 70% (14 companies return $0) Exit Distribution: - Failures: 14 companies @ $0 = $0 - Low Exits: 4 companies @ $8M exit value = $738,000 (4.1% initial ownership × 50% dilution = 2.05% at exit) - Medium Exits: 1 company @ $25M exit value = $256,250 (4.1% initial ownership × 60% dilution = 1.64% at exit) - High Exits: 1 company @ $75M exit value = $922,500 (4.1% initial ownership × 70% dilution = 1.23% at exit) Total Portfolio Returns: $1,916,750 Less Preferred Return (8% × $5M × 7 years avg): $2,800,000 Preferred Return Shortfall: ($883,250) Carried Interest: $0 (no carry until preferred return met) Net LP Returns: $1,916,750 TVPI: 0.38x IRR: -11% RETURN PROJECTIONS - BASE CASE Failure Rate: 60% (12 companies return $0) Exit Distribution: - Failures: 12 companies @ $0 = $0 - Low Exits: 5 companies @ $10M exit value = $1,025,000 (4.1% initial ownership × 50% dilution = 2.05% at exit) - Medium Exits: 2 companies @ $30M exit value = $984,000 (4.1% initial ownership × 60% dilution = 1.64% at exit) - High Exits: 1 company @ $100M exit value = $1,230,000 (4.1% initial ownership × 70% dilution = 1.23% at exit) Total Portfolio Returns: $3,239,000 Less Preferred Return (8% × $5M × 7 years avg): $2,800,000 Profit Above Preferred: $439,000 Carried Interest (18%): $79,020 Net LP Returns: $3,159,980 TVPI: 0.63x IRR: -6% RETURN PROJECTIONS - UPSIDE CASE Failure Rate: 50% (10 companies return $0) Exit Distribution: - Failures: 10 companies @ $0 = $0 - Low Exits: 6 companies @ $15M exit value = $1,845,000 (4.1% initial ownership × 50% dilution = 2.05% at exit) - Medium Exits: 3 companies @ $50M exit value = $2,460,000 (4.1% initial ownership × 60% dilution = 1.64% at exit) - High Exits: 1 company @ $150M exit value = $1,845,000 (4.1% initial ownership × 70% dilution = 1.23% at exit) Total Portfolio Returns: $6,150,000 Less Preferred Return (8% × $5M × 7 years avg): $2,800,000 Profit Above Preferred: $3,350,000 Carried Interest (18%): $603,000 Net LP Returns: $5,547,000 TVPI: 1.11x IRR: 1.5% RETURN PROJECTIONS - OPTIMISTIC CASE Failure Rate: 40% (8 companies return $0) Exit Distribution: - Failures: 8 companies @ $0 = $0 - Low Exits: 7 companies @ $20M exit value = $2,870,000 (4.1% initial ownership × 50% dilution = 2.05% at exit) - Medium Exits: 3 companies @ $75M exit value = $3,690,000 (4.1% initial ownership × 60% dilution = 1.64% at exit) - High Exits: 2 companies @ $200M exit value = $4,920,000 (4.1% initial ownership × 70% dilution = 1.23% at exit) Total Portfolio Returns: $11,480,000 Less Preferred Return (8% × $5M × 7 years avg): $2,800,000 Profit Above Preferred: $8,680,000 Carried Interest (18%): $1,562,400 Net LP Returns: $9,917,600 TVPI: 1.98x IRR: 10.5% FUND-RETURNING SCENARIO (3.0x TVPI TARGET) To achieve 3.0x TVPI ($15M total returns to LPs): Required Gross Portfolio Returns: $18,300,000 Realistic Path: - 2 companies exit at $250M+ with 1.2% ownership = $6,000,000 - 3 companies exit at $75-100M with 1.6% ownership = $4,200,000 - 5 companies exit at $25-50M with 2.0% ownership = $6,500,000 - 10 companies fail or return minimal capital = $1,600,000 Total: $18,300,000 gross returns COMPETITIVE ADVANTAGES 1. Market Foresight: 18-24 month advance visibility through NCPDP, NABP, NCPA board positions providing early insight into regulatory changes and payment pathway developments 2. Proprietary Deal Flow: Direct access to pharmacy ecosystem founders through governance roles and standards organizations 3. Value-Add Capabilities: Regulatory guidance, standards adoption support, and deployment assistance in community, rural, and underserved practice settings 4. Network Effects: Deep connections across independent pharmacies, chains, and pharmacy organizations for customer introductions and pilot programs 5. Timing Advantage: Policy enablement (CMS ACCESS, LEAD models) creating immediate infrastructure demand INVESTMENT CRITERIA Must-Haves: - Addresses pharmacy workflow, payment infrastructure, data interoperability, compliance, or care delivery enablement - Founder with pharmacy/healthcare domain expertise or deep understanding of pharmacy operations - Clear path to revenue within 12 months of investment - Defensible technology, network effects, or regulatory moat - Strong alignment with regulatory trends and reimbursement pathway evolution Nice-to-Haves: - Existing pharmacy customer traction or pilot programs - Standards-based approach (NCPDP, HL7, FHIR compliance) - Native integration capabilities with existing pharmacy management systems - Pharmacist founder or co-founder on the team - Participation from strategic pharmacy industry angels DEPLOYMENT TIMELINE Year 1 (2025): $1,800,000 deployed (8-10 initial investments) Year 2 (2026): $1,350,000 deployed (6-8 initial investments) Year 3 (2027): $900,000 deployed (4-6 initial investments + follow-ons) Years 4-5 (2028-2029): $450,000 reserved (follow-on investments in top performers) EXIT TIMELINE Years 1-5 (2025-2029): Active investment period Years 6-8 (2030-2032): Early exits begin (strategic acquisitions, secondary sales) Years 9-12 (2033-2036): Major exits expected (larger acquisitions, potential IPOs) FUND PERFORMANCE METRICS Target Metrics: - TVPI: 3.0x+ (top quartile) - DPI: 2.5x+ (cash returned to LPs) - IRR: 25%+ (top quartile) - Loss Ratio: <50% (better than industry average) Benchmark Comparison: - Top Quartile Seed Funds: 3.5x+ TVPI, 30%+ IRR - Median Seed Funds: 1.8x TVPI, 15% IRR - Healthcare Seed Funds: 2.2x TVPI, 18% IRR - Pharmacy Innovator Fund Target: 3.0x TVPI, 25% IRR RISK FACTORS 1. Regulatory Risk: Changes to pharmacy scope of practice, reimbursement models, or federal healthcare policy could impact portfolio company viability 2. Market Consolidation Risk: Continued consolidation of independent pharmacies could reduce addressable market for B2B solutions 3. Technology Integration Risk: Legacy pharmacy systems and resistance to change could slow adoption of new infrastructure 4. Competition Risk: Large healthcare IT vendors (Epic, Cerner, Surescripts) entering pharmacy infrastructure space 5. Execution Risk: First-time fund manager without prior institutional fund track record MITIGATION STRATEGIES 1. Portfolio Diversification: 20 companies across multiple pharmacy infrastructure subsectors reduces single-point failure risk 2. Infrastructure Focus: Targeting enabling infrastructure vs. consumer-facing solutions provides more defensible positioning 3. Regulatory Expertise: Deep involvement in standards organizations and policy development provides advance warning and adaptation capability 4. Founder Selection: Rigorous screening for domain expertise, execution capability, and market timing 5. Conservative Modeling: Base case assumes 60% failure rate and modest exit multiples, with upside scenarios requiring achievable outcomes LP REPORTING SCHEDULE Quarterly Reports: Portfolio updates, NAV calculations, capital call notices, distribution notices Annual Reports: Audited financial statements, K-1 tax documents, comprehensive performance review Ad Hoc Communications: Material events, new investments, exits, significant portfolio developments FUND ADMINISTRATION Administrator: Decile Group (full-service fund administration) Legal Counsel: Provided through Decile Start Fund structure Accounting: Provided through Decile Start Fund structure Compliance: Provided through Decile Start Fund structure Banking: Established through Decile Start Fund structure CONTACT INFORMATION Christian Tadrus, PharmD Investment Lead, Pharmacy Innovator Fund Tadrus Advisory Group, LLC Email: christian@tadrusadvisory.group Phone: 660.998.0291 Fund Website: https://decilepro.com/access/tag This Fund Sheet was prepared for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Pharmacy Innovator Fund is offered only to qualified investors pursuant to applicable exemptions from registration under federal and state securities laws.
Good morning! One of our potential LPs is trying to access our data room. I provided them with the direct link. They were prompted to create an account, which they did however it did not lead to the data room but rather led to a dashboard where they can search for funds -- and our fund is not even in the list!!!!!
I ask them to try the link again and now it is asking them to sign a subscription (they are not ready to do that) and prepare their funds for wire! They just want to review the data room....
Can someone help me to help them?
They are a bit annoyed so anything we can do quickly would be appreciated!! THANK YOU!
Hello! I need to send an email to one of the stages in recruiting panel. I only see option Pipeline Prospect (default), how can I select everyone in this specific stage as recipients of the email?
Hello! I just sent out a bulk mailing to 342 contacts. There was an error in the send so that the outbound was tried twice (the doubled email was not sent, so the system caught it and the error said the second email was not sent because it was a duplicate within 24hours).
However, Hub thinks that I have exceeded my daily limit of 500 (which I have not) and will not let me re-send the missing prospects.
Can someone please help? I have about 80 (of the 342) that did not send.
Hi, tried to request missing tax info via the auto-email function, got this when I clicked to send email: "Failed to find or create tax notification email template, please contact support."
When you add an image to an email by pasting it in (CTRL-V) it is stored inline in the email. If you use the toolbar it gets stored on DecileHub server and referenced.
Inline images are not displaying properly in Thunderbird email client. I do not know if that is a peculiarity of Thunderbird with inline images or an issue with how DecileHub sends inline images.
There is value to be able to choose between inline vs. image references but:
This behavior should be documented, and
It should be possible to tell whether a picture is inline or referenced without right click open in new tab
Thunderbird issue shoudl be fixed unless it is a Thunderbird peculiarity with inline images.
Regardless of where I am working, Hub keeps toggling the switch entity button in the upper left hand corner, so my screen keeps flashing the drop down menu to switch between the Fund, GP and Manco entities. Also it is running slow...probably caused by the toggling.
Hey guys, I published an event on hub we're creating for this saturday. We've sent it to around 100 people, but we only see there's 1 page view, which isn't right. Could you please look into it? Thanks https://cabraventurepartners.decilehub.com/e/venturein_fwb
Decile Hub MCP integration: `create_multiple_prospects` and `create_or_update_prospect` both fail with HTTP 400.
API response: ``` {"error":{"code":"bad_request","message":"param is missing or the value is empty or invalid: prospects","field":"prospects"}} ```
The MCP tool's JSON schema exposes `people` and `organizations` as the payload fields, but Decile's API expects `prospects`. The wrapper isn't translating the payload before forwarding.
Read operations work fine (`get_pipeline`, `get_prospects`, `list_organizations`, `debug_api_request` all return data), so auth and the API key are not the issue. Only writes are broken.
Reproducible with any valid pipeline_id + stage_id + people array. Confirmed across multiple payload variations (people only, people + organizations, with/without optional fields).
The development team has been working overtime to make Decile Hub the leading Agentic VC platform. Nearly everything can be done on Hub through APIs and MCP. Some highlights:
🔥 Significant speed increases, including faster AI Toolkits 🔥 Massive File system upgraded, making this #1 🔥 Major user interface upgrades with navigation and buttons 🔥 Upgraded the back office and Decile Pro experience 🔥 Testing Decile Magic to discover LPs with customers
We've been caffeinating our servers and teaching our AI new tricks. Your Hub now moves faster than venture capital gossip and thinks smarter than your favorite unicorn founder.
Here are many more upgrades, and please reply with anything that you want us to build.
💠 API & Integrations: Developer Power Comprehensive API expansion enables deeper integrations and automation, supporting everything from file management to pipeline execution with enhanced security controls. ‣ New entity and capital account endpoints ‣ Direct file attachment to specific records ‣ Pipeline action execution via API calls ‣ Enhanced permission controls for user tokens ‣ MCP integration reaches full API parity
🤖 AI Toolkits: Enhanced Intelligence Massive speed improvements make AI interactions lightning-fast, while new LP Research capabilities help you identify and analyze potential limited partners with unprecedented efficiency. ‣ AI processing speeds dramatically increased globally ‣ Decile Magic LP Research enters beta testing ‣ Smart prospect analysis provides actionable insights ‣ Real-time customer feedback improves recommendations
📺 User Interface: Polished Navigation A refreshed design language creates cleaner, more intuitive workflows across all Hub pages, reducing visual noise while improving information hierarchy. ‣ Cleaner page layouts with better spacing ‣ Stronger visual hierarchy guides user focus ‣ Sticky navigation elements improve table browsing ‣ Action buttons moved for easier access
🗄️ File System: Blazing Performance File upload capabilities expand while interface improvements make document management more intuitive and responsive. ‣ Configurable upload size limits per account ‣ Faster navigation and improved search functionality ‣ Direct attachment workflows save multiple steps ‣ Enhanced preview capabilities across file types
👥 Pipeline Management: Automation Excellence Pipeline workflows become more reliable while new automation features eliminate manual tasks and reduce prospect management overhead. ‣ Link-click automations prevent backward stage movement ‣ Closing pipeline automations fire consistently ‣ Custom data points integration via API ‣ Enhanced prospect filtering delivers faster results
🏦 Back Office: Capital Management Streamlined capital account infrastructure and improved processing speeds eliminate bottlenecks while preparing the foundation for next-generation fund administration features. ‣ Capital account database restructuring begins rollout ‣ Enhanced LP onboarding reduces friction significantly ‣ Wire confirmation notifications reach all stakeholders ‣ Cap table improvements for all entities
Hi. We have people clicking and viewing this file but not being added to Syndicate LP funnel. They are prospects who are in directory but not in any Pipeline. That may be the issue.
Decile Group Inc. uses cookies for our website to function properly; some are optional and help deliver a personalized and enhanced experience. By clicking "Allow all", you consent to store cookies on your device in accordance with our cookie policy. You can reject all non-essential processing by choosing to accept only necessary cookies. To learn more check Cookie Policy